2 research outputs found
The combined use of serum neurotensin and IL-8 as screening markers for colorectal cancer
This pilot study aimed to determine the feasibility of serum
neurotensin/IL-8 values being used as a screening tool for colorectal
cancer. Fifty-six patients and 15 healthy controls were assigned to
seven groups according to their disease entity based on theater records
and histology report. Blood samples for neurotensin and IL-8 were
measured using an enzyme-linked immunosorbent assay. There were no
differences in the clinical and biochemical parameters of patients and
controls. Group (p = 0.003) and age (p = 0.059, marginally significant)
were independent predictors of neurotensin plasma values. Neurotensin (p
= 0.004) and IL-8 (p = 0.029) differed between healthy and colorectal
cancer patients. Neurotensin values differentiate the control group from
all remaining groups. The value of plasma neurotensin a parts per
thousand currency sign54.47 pg/ml at enrollment selected by receiver
operating characteristic (ROC) curves demonstrated a sensitivity of 77
%, specificity of 90 %, and an estimate of area under ROC curve
(accuracy) of 85 % in predicting colorectal cancer. At enrollment, the
value of plasma IL-8 a parts per thousand yen8.83 pg/ml had a
sensitivity of 85 %, specificity 80 %, and an estimate of area under
ROC curve (accuracy) of 81 % in predicting colorectal cancer. IL-8
should be used complementary to neurotensin due to its lower
specificity. None of the colorectal cancer patients displayed a
combination of high neurotensin and low IL-8 values (beyond cutoffs). It
seems that a blood neurotensin/IL-8 system may be used as a screening
tool for colorectal cancer, but much has to be done before it is
validated in larger-scale prospective studies